Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for th

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Expert Opinion's
Reply to topic
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for th
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Mon Jun 23, 2008 1:31 pm Reply with quote


Expert Opinion on Investigational Drugs , July 2008, Vol. 17, No. 7, Pages 1127-1136.
<br/>
The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the management of chronic myeloid leukemia (CML). Imatinib mesilate therapy has significantly improved the prognosis of CML. A minority of patients in chronic-phase ...

Read more...

Source: Expert Opinion: Expert Opinion on Investigational Drugs: Table of Contents
Table of Contents for Expert Opinion on Investigational Drugs. List of articles from both the latest and ahead of print issues.
View user's profileSend private message
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for th
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Expert Opinion's
 Reply to topic  
Forum Map
Site Map